Adaptimmune Therapeutics plc (ADAP) Is Worth Investing In

Adaptimmune Therapeutics plc (NASDAQ:ADAP) concluded the trading at $2.11 on Thursday, March 17 with a rise of 14.67% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $1.84 and 5Y monthly beta was reading 2.02 with its price kept floating in the range of $1.80 and $2.11 on the day. Considering stock’s 52-week price range provides that ADAP hit a high price of $6.86 and saw its price falling to a low level of $1.69 during that period. Over a period of past 1-month, stock came subtracting -33.44% in its value.

The Top 5 Ways to Trade a Potential $800 Billion Metaverse
According to analysts at Emergen Research, the metaverse market could be worth up to $828.95 billion by 2028. When you sign up for our report “The Top 5 Metaverse Stocks to Buy for 2022,” you’ll get access to the the five best metaverse stocks in our report, along with a free subscription to DailyMarketAlerts newsletter to help you get in on the hottest stocks of tomorrow.
Click here to sign up for the FREE Report & become a subscriber to DailyMarketAlerts Newsletter


With its current market valuation of $329.60 million, Adaptimmune Therapeutics plc is set to declare its quarterly results on Feb 23, 2022 – Feb 28, 2022. Analysts are in estimates of -$0.06 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.7 for 2021 with estimates of that growing to -$0.99 in next year. These estimates are suggesting current year growth of 22.20% for EPS and -41.40% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $77.76 million. They suggested that in the process company could generate revenue of as low as $400k which could climb up to $159 million to hit a high. The average estimate is representing an increase of 5,077.10% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $82.48 million in 2021, which will be 1,983.90% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review ADAP stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

According to ratings assigned by 8 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 4 of them are recommending Adaptimmune Therapeutics plc (ADAP) as a Hold, while 3 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 1 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the ADAP stock which is currently positioned at 0. It further provides that stock’s current price level is -8.89% away from its 20-day simple moving average and is -24.57% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 40.13 while volatility remained at 9.38% over the past week which changes to 7.93% when measuring it over the past month. Beta is valued at 2.19, while measure of average true range or ATR is currently at 0.17. In predicting price targets of as low as $2.00 and as high as $9.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $6.00. Stock’s current price level is 5.21% above from estimated low price target while it is -326.54% below the estimated high; and even if the ADAP’s share succeeded to reach the median price of $7.00, then the outlook of -231.75% could come to the excitement of the investors.

In comparing Adaptimmune Therapeutics plc (ADAP)’s stock with other industry players […]

source Adaptimmune Therapeutics plc (ADAP) Is Worth Investing In

Leave a Reply